Q3 EPS Forecast for ProQR Therapeutics Decreased by Analyst

ProQR Therapeutics N.V. (NASDAQ:PRQR) – Research analysts at HC Wainwright dropped their Q3 2026 EPS estimates for ProQR Therapeutics in a report issued on Monday, August 17th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.09). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for ProQR Therapeutics’ Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.43) EPS and FY2027 earnings at ($0.43) EPS.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.04. The firm had revenue of $10.00 million during the quarter, compared to analyst estimates of $4.56 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%.

PRQR has been the topic of several other research reports. Weiss Ratings raised shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Wednesday, May 27th. Chardan Capital decreased their price target on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Finally, JonesTrading dropped their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.33.

ProQR Therapeutics Price Performance

NASDAQ:PRQR opened at $2.15 on Wednesday. The company has a market capitalization of $226.52 million, a price-to-earnings ratio of -4.67 and a beta of 0.07. The business has a 50 day moving average of $1.76 and a 200 day moving average of $1.66. ProQR Therapeutics has a 1-year low of $1.33 and a 1-year high of $3.10.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors have recently bought and sold shares of the stock. Ikarian Capital LLC boosted its stake in ProQR Therapeutics by 67.2% during the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after acquiring an additional 600,000 shares in the last quarter. Privium Fund Management B.V. lifted its holdings in shares of ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock valued at $10,823,000 after purchasing an additional 359,475 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of ProQR Therapeutics by 73.2% during the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after purchasing an additional 277,749 shares during the last quarter. Millennium Management LLC grew its stake in shares of ProQR Therapeutics by 80.8% in the 4th quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 194,369 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in ProQR Therapeutics by 86.3% during the 3rd quarter. Two Sigma Investments LP now owns 417,300 shares of the biopharmaceutical company’s stock valued at $889,000 after buying an additional 193,260 shares in the last quarter. 32.65% of the stock is owned by institutional investors.

Insider Buying and Selling

In other ProQR Therapeutics news, CEO Boer Daniel Anton De purchased 150,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was bought at an average price of $1.74 per share, with a total value of $261,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at $522,000. The trade was a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bart Filius purchased 150,000 shares of the business’s stock in a transaction that occurred on Friday, July 17th. The stock was bought at an average price of $1.72 per share, for a total transaction of $258,000.00. Following the acquisition, the director owned 300,000 shares of the company’s stock, valued at $516,000. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders bought 600,000 shares of company stock worth $988,500. Corporate insiders own 8.40% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.